Invesco
TARA icon

Invesco’s Protara Therapeutics TARA Stock Holding History

Invesco’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
26,856
+8,895
+50% +$42.3K ﹤0.01% 3730
2026
Q1 		$93.6K Buy
17,961
+447
+3% +$2.65K ﹤0.01% 3633
2025
Q4 		$93.3K Sell
17,514
-7,655
-30% -$42.6K ﹤0.01% 3645
2025
Q3 		$109K Buy
25,169
+1,234
+5% +$4K ﹤0.01% 3673
2025
Q2 		$72.5K Buy
+23,935
New +$82.6K ﹤0.01% 3690
2015
Q3 		– Sell
-9
Closed -$6K – 3976
2015
Q2 		$6K Buy
+9
New +$5.57K ﹤0.01% 4135

Other funds holding TARA

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Integral Health Asset Management
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Invesco's TARA Position: Q2 2026 in Review

Invesco increased its Protara Therapeutics (TARA) stake by 50% in Q2 2026, buying an estimated $42.3K and bringing the position to 26,856 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #3730.

Invesco first reported a position in TARA in Q2 2015 and has held it in 6 quarters since. The position peaked at $109K in Q3 2025. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Invesco held 26,856 shares of Protara Therapeutics worth $103K as of Q2 2026.
  • Invesco bought 8,895 Protara Therapeutics shares in Q2 2026, an estimated $42.3K.
  • Protara Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3730 holding.
  • Invesco first reported a position in Protara Therapeutics in Q2 2015 and has held it in 6 quarters since.
  • Invesco's Protara Therapeutics position peaked at $109K in Q3 2025.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.